An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
vericiguat arm
Female and male patients ≥ 18 years of age who are naïve to vericiguat treatment
Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization)
Decision to initiate treatment with vericiguat as per the local approved label
Signed informed consent
control arm
Aged 18 or over at baseline
Only patients receiving SoC for chronic heart failure (no history of receiving vericiguat prior to the index date)
Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization)
You may not be if
vericiguat arm
Participation in other investigational program with interventions outside of routine clinical practice
Contra-indications according to the local marketing authorization label
control arm
Patients who have started therapy with vericiguat for chronic heart failure at baseline
Contra-indications according to the vericiguat local marketing authorization label